Contract manufacturers must continue to meet global, non-pandemic needs. Many are ramping up to respond to the growing demand for cell and gene therapies — novel and complex biologics at the forefront of innovation for treatment of severe diseases, such as cancer — that have suffered from supply delays.

Two new and promising CDMOs have recently entered the scene in this buzzing sector. The Center for Breakthrough Medicines, set to be fully operational by 2022, is promising to be the biggest cell and gene therapy CDMO in the world, using cutting-edge technologies to provide a one-stop shop with end-to-end advanced therapy production…

Read full story